Immunotherapy Archives

News and Trends 18 Nov 2022

MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma

KAHR Medical, a clinical stage biotech company that is developing a treatment for solid tumors and blood cancers has received investment from the Myeloma Investment Fund (MIF). MIF has made the investment to explore the potential of DSP107, KAHR’s leading immunotherapy drug candidate for the treatment of multiple myeloma. “We are thrilled to partner with […]

November 18, 2022 - 3 minutesmins - By Liza Laws

brain cancer glioblastoma divide and conquer

News and Trends 18 Nov 2022

NW Bio reports positive top-line results from phase 3 glioblastoma trial

Northwest Biotherapeutics, which is developing DCVax personalized immune therapies for solid tumor cancers, yesterday (November 17) reported that both median and long tail survival were increased in both newly diagnosed and recurrent glioblastoma. The brain tumor cancer patients were treated with DCVax-L and in its phase 3 clinical trial met both the primary and secondary […]

November 18, 2022 - 4 minutesmins - By Liza Laws

News and Trends 15 Nov 2022

First patient dosed in Nouscom colorectal cancer study

Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized immunotherapies, says the first patient has been dosed in a randomized phase 2 clinical trial evaluating NOUS-209 in combination with anti-PD1 checkpoint inhibitor (CPI) pembrolizumab versus pembrolizumab alone. NOUS-209 is an off-the-shelf immunotherapy targeting 209 specific neoantigens for the treatment of mismatch repair/microsatellite instable high […]

November 15, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 14 Nov 2022

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […]

November 14, 2022 - 3 minutesmins - By Jim Cornall

More News! 8 Nov 2022

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

ISA Pharmaceuticals B.V, a Netherlands-based clinical stage biotech developing immunotherapies to treat cancers and infectious diseases has had a phase 1 clinical study published. The study, using ISA Pharmaceuticals’ Amplivant adjuvant and synthetic long peptide (SLP) therapeutic vaccine technology was published by Leiden University Medical Centre (LUMC) in the Journal for ImmunoTherapy for Cancer. It […]

November 8, 2022 - 2 minutesmins - By Liza Laws

News and Trends 4 Nov 2022

Creative Medical Technology Holdings announces FDA clearance of diabetes drug

Creative Medical Technology Holdings yesterday (November 3) announced its investigational new drug (IND) application has been cleared by the U.S. Food and Drug Administration (FDA). This will enable the company to start initiating a clinical trial for type 1 diabetes using AlloStem. The primary objective of the study is to evaluate Allostem in patients with […]

November 4, 2022 - 3 minutesmins - By Liza Laws

News and Trends 31 Oct 2022

Reprogramming immune cells can fight melanoma

A new way of reprogramming immune cells to shrink or kill off cancer cells has been shown to work in the otherwise hard-to-treat skin cancer, melanoma. The University of Bristol, in the U.K. led the discovery, which has been published in Advanced Science. It demonstrates a new way to clear early stage pre-cancerous and even […]

October 31, 2022 - 3 minutesmins - By Jim Cornall

News and Trends 26 Oct 2022

First patient dosed in trial to assess predictive performance of immuno-oncology therapy

The first patient has been dosed at the Macquarie University Hospital in Sydney as part of a clinical trial to evaluate whether a drug can predict patient response to immuno-oncology therapy targeting a number of solid tumor types. ImaginAb Inc. is a biotech company developing 89Zr crefmirlimab berdoxam (CD8 ImmunoPET) imaging agent and next generation […]

October 26, 2022 - 3 minutesmins - By Liza Laws

News and Trends 26 Oct 2022

New UK spinout VacV Biotherapeutics emerges from stealth to work on cancer immunotherapies

VacV Biotherapeutics, a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its pipeline of pre-clinical assets with best-in-class potential, towards the clinic. VacV Biotherapeutics has spun out of Barts Cancer Institute and Queen Mary University of London following 20 years of research by immunotherapy experts Yaohe Wang, Nicholas Lemoine, […]

October 26, 2022 - 2 minutesmins - By Jim Cornall

Anastasiia Slynko neobe therapeutics cancer

Startup Scout 19 Oct 2022

Neobe Therapeutics breaks down tumor defenses with bacteria

Many cancer patients cannot benefit from cancer immunotherapy because their tumors are protected from the immune system. Neobe Therapeutics’ bacterial therapy is designed to strip the tumors of their protective barriers. The immune system is very good at fighting tumors, and cancer immunotherapies are often able to supercharge our natural defenses to great effect. However, […]

October 19, 2022 - 4 minutesmins - By Jonathan Smith

News and Trends 12 Oct 2022

Agreement signed to advance therapy for autoimmune disease

HanAll Biopharma’s licensed partner, Harbour BioMed, has signed an exclusive sublicense agreement with CSPC NBP Pharmaceutical Co., Ltd for an advanced inhibitor. The agreement is for HanAll’s neonatal Fc receptor (FcRn) inhibitor batoclimab which is one of the most advanced being developed in Greater China. The companies say it has the potential to become a […]

October 12, 2022 - 3 minutesmins - By Liza Laws

News and Trends 11 Oct 2022

Accelerated application for drug to help immunodeficiency submitted by Pharming

A marketing authorization application (MAA) has been submitted by Dutch company Pharming Group, to the European Medicines Agency (EMA) for a rare, primary immunodeficiency in adults and adolescents 12 years and older. Activated phosphonide 3-kinase delta syndrome (APDS), first discovered in 2013, is caused by genetic variants in either one of two identified genes known […]

October 11, 2022 - 4 minutesmins - By Liza Laws

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Immunotherapy

MIF invests in KAHR to explore lead immunotherapy drug for multiple myeloma

NW Bio reports positive top-line results from phase 3 glioblastoma trial

First patient dosed in Nouscom colorectal cancer study

Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy

ISA Pharmaceuticals’ Amplivant adjuvant boosts immune response in SLP immunotherapy

Creative Medical Technology Holdings announces FDA clearance of diabetes drug

Reprogramming immune cells can fight melanoma

First patient dosed in trial to assess predictive performance of immuno-oncology therapy

New UK spinout VacV Biotherapeutics emerges from stealth to work on cancer immunotherapies

Neobe Therapeutics breaks down tumor defenses with bacteria

Agreement signed to advance therapy for autoimmune disease

Accelerated application for drug to help immunodeficiency submitted by Pharming

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Grab your free report on 3D organoids and explore their future potential

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!